↓ Skip to main content

Cochrane Database of Systematic Reviews

Chemotherapy for high-grade glioma

Overview of attention for article published in Cochrane database of systematic reviews, October 2002
Altmetric Badge

Mentioned by

1 Wikipedia page


40 Dimensions

Readers on

85 Mendeley
Chemotherapy for high-grade glioma
Published in
Cochrane database of systematic reviews, October 2002
DOI 10.1002/14651858.cd003913
Pubmed ID

Lesley Stewart, Sarah Burdett


Trials on the effect of systemic chemotherapy on survival and recurrence in adults with high-grade glioma have had inconclusive results. We undertook a systematic review and meta-analysis to assess the effects of such treatment on survival and recurrence. To compare radiotherapy plus chemotherapy with radiotherapy alone in completely resected adults with high-grade glioma. To investigate whether or not pre-defined patient subgroups benefit more or less from chemotherapy. MEDLINE and CancerLit searches were supplemented with information from trial registers and by hand searching relevant meeting proceedings and by discussion with relevant trialists and organisations. These searches were carried out in June 1997, June 1999 and December 2000. Trials comparing radiotherapy versus radiotherapy + chemotherapy were eligible for inclusion provided that they randomized adult patients using a method which precluded prior knowledge of treatment assignment. A quantitative meta-analysis using updated information from individual patients from all available randomized trials was carried out. Data from all patients randomized in all eligible trials were sought directly from those responsible. Updated information on survival and date of follow-up were obtained, as were details of treatment allocation, date of randomization, age, sex, histological cell type, stage and performance status. To avoid potential bias, information was requested for all randomized patients including those who had been excluded from the investigators' original analyses. All analyses were done on an intention to treat basis on the endpoint of survival. For trials using cisplatin-based regimens, subgroup analyses by age, sex, histological cell type, tumour stage and performance status were also done. Data from 12 randomized trials and 3004 patients were included. The results show a significant prolongation of survival associated with chemotherapy, with a hazard ratio of 0.85 (95% CI 0.78-0.91, p=0.00004) or 15% relative decrease in the risk of death. This is equivalent to an absolute increase in one year survival rate of 6% (95% confidence interval 3% to 9%) from 40% to 46% and a two-month increase in median survival time (95% confidence interval one month to three months). There was no evidence that the effect of chemotherapy was different in any group of patients defined by age, sex, histology, performance status or extent of resection. This small but clear improvement in survival from chemotherapy encourages further study of drug treatment of these tumours

Mendeley readers

The data shown below were compiled from readership statistics for 85 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 2 2%
Italy 1 1%
United States 1 1%
Unknown 81 95%

Demographic breakdown

Readers by professional status Count As %
Researcher 13 15%
Student > Master 10 12%
Student > Bachelor 10 12%
Student > Ph. D. Student 9 11%
Student > Doctoral Student 7 8%
Other 15 18%
Unknown 21 25%
Readers by discipline Count As %
Medicine and Dentistry 34 40%
Nursing and Health Professions 7 8%
Biochemistry, Genetics and Molecular Biology 3 4%
Engineering 3 4%
Neuroscience 2 2%
Other 12 14%
Unknown 24 28%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 March 2010.
All research outputs
of 22,783,848 outputs
Outputs from Cochrane database of systematic reviews
of 12,314 outputs
Outputs of similar age
of 48,235 outputs
Outputs of similar age from Cochrane database of systematic reviews
of 24 outputs
Altmetric has tracked 22,783,848 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 12,314 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 30.4. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 48,235 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.